BioTechniques (Sep 2022)
Methods to evaluate the impact of SARS-CoV-2 nucleocapsid mutations on antigen detection by rapid diagnostic tests
- Bryan C Tieman,
- Stephen Kovacs,
- Mary A Rodgers,
- Aurash Mohaimani,
- Svetoslava Gregory,
- David Christensen,
- Jeffrey A Moore,
- Lici Schurig-Briccio,
- James Hartnett,
- Alak Kar,
- Aaron Leeman,
- Angel Palmer,
- Lauren Rogers,
- Brian Dragoo,
- Steven Muszynski,
- Deborah Noblesmith,
- Samantha Gardner,
- Abigail Snipe-Bushey,
- Anna Kill,
- Xinxin Luo,
- Sneha Cherukuri,
- Tracey Rae,
- Christopher C Marohnic,
- Gavin A Cloherty,
- Anthony Scott Muerhoff,
- Philip M Hemken
Affiliations
- Bryan C Tieman
- 1Biologics Discovery, Abbott Laboratories, Abbott Park, IL 60064, USA
- Stephen Kovacs
- 2ARDx, Abbott Laboratories, Westbrook, ME 04092, USA
- Mary A Rodgers
- 3ID Core Research, Abbott Laboratories, Abbott Park, IL 60064, USA
- Aurash Mohaimani
- 3ID Core Research, Abbott Laboratories, Abbott Park, IL 60064, USA
- Svetoslava Gregory
- 1Biologics Discovery, Abbott Laboratories, Abbott Park, IL 60064, USA
- David Christensen
- 1Biologics Discovery, Abbott Laboratories, Abbott Park, IL 60064, USA
- Jeffrey A Moore
- 1Biologics Discovery, Abbott Laboratories, Abbott Park, IL 60064, USA
- Lici Schurig-Briccio
- 1Biologics Discovery, Abbott Laboratories, Abbott Park, IL 60064, USA
- James Hartnett
- 1Biologics Discovery, Abbott Laboratories, Abbott Park, IL 60064, USA
- Alak Kar
- 1Biologics Discovery, Abbott Laboratories, Abbott Park, IL 60064, USA
- Aaron Leeman
- 2ARDx, Abbott Laboratories, Westbrook, ME 04092, USA
- Angel Palmer
- 2ARDx, Abbott Laboratories, Westbrook, ME 04092, USA
- Lauren Rogers
- 2ARDx, Abbott Laboratories, Westbrook, ME 04092, USA
- Brian Dragoo
- 2ARDx, Abbott Laboratories, Westbrook, ME 04092, USA
- Steven Muszynski
- 2ARDx, Abbott Laboratories, Westbrook, ME 04092, USA
- Deborah Noblesmith
- 2ARDx, Abbott Laboratories, Westbrook, ME 04092, USA
- Samantha Gardner
- 2ARDx, Abbott Laboratories, Westbrook, ME 04092, USA
- Abigail Snipe-Bushey
- 2ARDx, Abbott Laboratories, Westbrook, ME 04092, USA
- Anna Kill
- 2ARDx, Abbott Laboratories, Westbrook, ME 04092, USA
- Xinxin Luo
- 3ID Core Research, Abbott Laboratories, Abbott Park, IL 60064, USA
- Sneha Cherukuri
- 3ID Core Research, Abbott Laboratories, Abbott Park, IL 60064, USA
- Tracey Rae
- 1Biologics Discovery, Abbott Laboratories, Abbott Park, IL 60064, USA
- Christopher C Marohnic
- 1Biologics Discovery, Abbott Laboratories, Abbott Park, IL 60064, USA
- Gavin A Cloherty
- 3ID Core Research, Abbott Laboratories, Abbott Park, IL 60064, USA
- Anthony Scott Muerhoff
- 1Biologics Discovery, Abbott Laboratories, Abbott Park, IL 60064, USA
- Philip M Hemken
- 1Biologics Discovery, Abbott Laboratories, Abbott Park, IL 60064, USA
- DOI
- https://doi.org/10.2144/btn-2022-0020
- Journal volume & issue
-
Vol. 73,
no. 3
pp. 136 – 141
Abstract
Mutations in the nucleocapsid of SARS-CoV-2 may interfere with antigen detection by diagnostic tests. We used several methods to evaluate the effect of various SARS-CoV-2 nucleocapsid mutations on the performance of the Panbio™ and BinaxNOW™ lateral flow rapid antigen tests and a prototype high-throughput immunoassay that utilizes Panbio antibodies. Variant detection was also evaluated by immunoblot and BIAcore™ assay. A panel of 23 recombinant nucleocapsid antigens (rAgs) were produced that included mutations found in circulating SARS-CoV-2 variants, including variants of concern. All mutant rAgs were detected by all assays, at a sensitivity equivalent to wild-type control (Wuhan strain). Thus, using a rAg approach, we found that the SARS-CoV-2 nucleocapsid mutations examined do not directly impact antigen detection or antigen assay performance.
Keywords
